{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:41Z","timestamp":1761897041649,"version":"3.37.3"},"reference-count":32,"publisher":"The Endocrine Society","issue":"8","funder":[{"DOI":"10.13039\/501100003197","name":"AIFA","doi-asserted-by":"publisher","award":["FARM6T9CET"],"award-info":[{"award-number":["FARM6T9CET"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DiabeteRicerca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1210\/jc.2019-00361","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T11:26:48Z","timestamp":1557228408000},"page":"3296-3302","source":"Crossref","is-referenced-by-count":11,"title":["Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-1428","authenticated-orcid":false,"given":"Olga","family":"Vaccaro","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lucisano","sequence":"additional","affiliation":[{"name":"CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Masulli","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Bonora","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[{"name":"Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela A","family":"Rivellese","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo B","family":"Giorda","sequence":"additional","affiliation":[{"name":"Diabetes Unit, ASL Torino 5, Chieri, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Mocarelli","sequence":"additional","affiliation":[{"name":"University Department of Laboratory Medicine, Hospital of Desio, Desio (MB), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Squatrito","sequence":"additional","affiliation":[{"name":"Diabetes Unit, University Hospital Garibaldi-Nesima of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Riccardi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Nicolucci","sequence":"additional","affiliation":[{"name":"CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"TOSCA.IT Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"issue":"6","key":"2019061916300712900_bib1","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2017.04.008","article-title":"Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes","volume":"130","author":"Paneni","year":"2017","journal-title":"Am J Med"},{"issue":"1","key":"2019061916300712900_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ecl.2017.10.011","article-title":"Personalizing glucose-lowering therapy in patients with type 2 diabetes and cardiovascular disease","volume":"47","author":"Inzucchi","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019061916300712900_bib3","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"issue":"22","key":"2019061916300712900_bib4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"2019061916300712900_bib5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2019061916300712900_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2019061916300712900_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"2019061916300712900_bib8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/archinte.164.13.1438","article-title":"Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial","volume":"164","author":"Vaccaro","year":"2004","journal-title":"Arch Intern Med"},{"volume-title":"National diabetes statistics report, 2017","year":"2017","author":"Centers for Disease Control and Prevention","key":"2019061916300712900_bib9"},{"issue":"8","key":"2019061916300712900_bib10","first-page":"S146","article-title":"Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population","volume":"24","author":"Wittbrodt","year":"2018","journal-title":"Am J Manag Care"},{"issue":"10166","key":"2019061916300712900_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"2019061916300712900_bib12","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"2019061916300712900_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/M18-1149","article-title":"Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 diabetes in low resource settings: synopsis of the World Organization guidelines second- and third-line medicines and type of insulin for control of blood glucose levels in non-pregnant adults with diabetes mellitus","volume":"169","author":"Roglic","year":"2018","journal-title":"Ann Intern Med"},{"issue":"12","key":"2019061916300712900_bib14","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"2019061916300712900_bib15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2019061916300712900_bib16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S2213-8587(18)30070-6","article-title":"The many faces of diabetes: addressing heterogeneity of a complex disease","volume":"6","author":"Sladek","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2019061916300712900_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.numecd.2012.09.003","article-title":"Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events: a randomized controlled trial","volume":"22","author":"Vaccaro","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2019061916300712900_bib18","first-page":"165","volume-title":"Constructing prediction trees from data: the RECPAM approach.","author":"Ciampi","year":"1992"},{"issue":"9","key":"2019061916300712900_bib19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jama.2015.0956","article-title":"The natural history of benign thyroid nodules","volume":"313","author":"Durante","year":"2015","journal-title":"JAMA"},{"issue":"29","key":"2019061916300712900_bib20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"2019061916300712900_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/joim.12859","article-title":"Precision medicine in type 2 diabetes","volume":"285","author":"Prasad","year":"2019","journal-title":"J Intern Med"},{"issue":"4","key":"2019061916300712900_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"2019061916300712900_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","year":"2019","journal-title":"Diab Vasc Dis Res"},{"issue":"21","key":"2019061916300712900_bib24","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"issue":"13","key":"2019061916300712900_bib25","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"17","key":"2019061916300712900_bib26","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2019061916300712900_bib27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2019061916300712900_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2019061916300712900_bib29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/dc18-0344","article-title":"Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data","volume":"41","author":"Dennis","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"2019061916300712900_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00592-018-1253-5","article-title":"Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis","volume":"56","author":"Vetrone","year":"2019","journal-title":"Acta Diabetol"},{"issue":"4","key":"2019061916300712900_bib31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2019061916300712900_bib32","unstructured":"Eli Lilly and Company. Trulicity\u00ae (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes. Available at: https:\/\/www.multivu.com\/players\/English\/8442751-lilly-trulicity-rewind-trialtype-2-diabetes\/. Accessed January 2019."}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-00361\/28554676\/jc.2019-00361.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/8\/3296\/28845499\/jc.2019-00361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T20:35:58Z","timestamp":1569357358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/8\/3296\/5485080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,5,6]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-00361","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"type":"print","value":"0021-972X"},{"type":"electronic","value":"1945-7197"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,5,6]]}}}